IDG16177 / Evotec, Ildong - LARVOL DELTA

In Vitro DILI Risk Assessment of IDG16177, a Potent and Selective GPR40 Agonist, for the Treatment of Type 2 Diabetes (ADA 2022) - "Fasiglifam induced a significant accumulation of GCA at 4 µM lower than the human Cmax of 10 µM, whereas IDG16177 showed no significant accumulation at 1 µM higher than the predicted human Cmax of 0.3 µM.IDG16177 did not have a significant effect in quantitative evaluation of the activity of various transcription factors, whereas treatment with 10 uM fasiglifam for 24 hours significantly increased the activities of peroxisome proliferator activating receptor (PPAR), activator protein 1 (AP-1) and nuclear respiratory factor 2 (NRF2), which were highly correlated with liver disease pathogenesis/progression. Interestingly, treatment with 10 μM IDG16177 for 48 h increased the activity of FXR, a master regulator of BA metabolism that inhibits BA absorption system and BA synthesis and promotes BA enterohepatic circulation, by 1.58-fold.These results show that IDG16177 has the advantage of having a low DILI potential compared to fasiglifam in addition to its..."

Late-breaking abstract • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics (clinicaltrials.gov) - P1; N=94; Recruiting; Sponsor: IlDong Pharmaceutical Co Ltd

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

[VIRTUAL] Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes (ADA 2021) - "Fasiglifam, a GPR40 agonist, was withdrawn from clinical development in Phase III due to DILI. And no phototoxicity was observed in in vitro 3T3 NRU study. These results shows that the potential for IDG-16177, a safe and effective GPR40 agonist, to treat patients with type 2 diabetes."

Late-breaking abstract • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • ABCC3

[VIRTUAL] IDG-16177, a Potent, Orally-Bioavailable GPR40 Agonist, Improves Glycemic Control and Glucose-Stimulated Insulin Secretion in Preclinical Studies (ADA 2021) - "IDG-16177 1 mg/kg showed similar effective in insulin secretion fasiglifam 10 mg/kg. These results show that IDG-16177 might be an effective drug candidate for treatment of type 2 diabetes."

Late-breaking abstract • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

[VIRTUAL] In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes (ADA 2021) - "Although IDG-16177 shows no signal at the cAMP pathway like fasiglifam, IDG-16177 (0.1∼3 μM)-treated group enhances more insulin secretion than fasiglifam (1∼10 μM) in HIT-T15 β cells. These studies support the potential utility of IDG-16177 for the treatment of type 2 diabetes."

Late-breaking abstract • PK/PD data • Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Ildong Pharmaceutical introduces new drug R&D projects at JP Morgan Healthcare Conference (Maekyung Media Group) - "Ildong Pharmaceutical will participate in the One-On-One Partnering of the JP Morgan Healthcare Conference, which will be held online until the 14th (US time), to introduce new drug research projects and related candidates for metabolic diseases...etc. It was announced on the 14th (Korean time)....First, in the field of metabolic diseases, IDG-16177, a new drug candidate for treating type 2 diabetes...Through this, non-clinical research and clinical sample development are in progress. An official at Ildong Pharmaceutical said, 'At this conference, we announced the company's promising new drug pipeline and held active meetings with companies that showed interest.'"

Preclinical • Type 2 Diabetes Mellitus